aap Implantate (AAQ1) AI Stock Analysis

• Market Cap: €22.37M
• Dividend Yield: N/A
• Average Volume (3M): 620.00
• Price to Earnings (P/E): ―
• Beta (1Y): -0.45
• Revenue Growth: -0.59%
• EPS Growth: 24.03%
• Country: DE
• Employees: 87
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): N/A
• Shares Outstanding: 14,716,976
• 10 Day Avg. Volume: 259
• 30 Day Avg. Volume: 620
• PEG Ratio: 0.09
• Price to Book (P/B): 1.20
• Price to Sales (P/S): 1.03
• P/FCF Ratio: -8.61
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 51 Neutral
• Price Target: €1.50 ▲(19.05% Upside)

The score is held back primarily by weak financial performance, driven by ongoing losses and negative operating/free cash flow, despite improved leverage and revenue growth. Technicals are relatively supportive with price above key averages and a positive MACD, but momentum indicators are stretched. Valuation is also constrained by a negative P/E that signals continuing unprofitability.

Positive Factors

Improved leverage (debt-to-equity)

A lower debt-to-equity ratio materially reduces financial risk and interest burden, improving flexibility to fund R&D and commercial expansion. Over 2–6 months, sustained low leverage supports resilience through surgical sales cycles and reduces refinancing vulnerability.

Revenue growth recovery

Positive revenue growth indicates improving product demand and market traction in orthopedics. If sustained, this trend supports scale benefits, better margin absorption of fixed costs, and strengthens the platform for distributor/clinic partnerships over the medium term.

Strong free cash flow growth rate

A large percentage increase in FCF signals operational improvement and progress toward cash generation. Even off a low base, continued FCF growth can enable self-funded investments in product development and post-sales service capabilities, improving long-term sustainability.

Negative Factors

Persistent negative profitability

Negative operating and reported profits show the company is not yet converting sales into sustainable earnings. Persisting margin deficits constrain reinvestment, make break-even distant, and can force pricing or cost trade-offs that weaken competitive positioning over months.

Negative operating and free cash flows

Ongoing negative cash generation creates reliance on external funding or equity dilution to finance operations and growth. Over a multi-month horizon this limits flexibility for marketing, new product launches, and inventory support in a device business with surgical timing spikes.

Negative return on equity

A negative ROE signals capital is not generating shareholder value and indicates weak operational efficiency. This undermines investor confidence, may raise cost of capital, and restricts the firm's ability to attract funding for product development and distribution expansion long term.

aap Implantate Business Overview & Revenue Model

Company Description

aap Implantate AG, a medical device company, develops, manufactures, and markets trauma products for orthopedics in Germany, the United States, and internationally. It offers LOQTEQ, an anatomical plating system for fracture treatment; and a range of cannulated screws, standard plates, and screws. The company sells its products directly to hospitals, buying syndicates, and hospital groups, as well as through a network of distributors under the aap brand name. aap Implantate AG was founded in 1990 and is headquartered in Berlin, Germany.

How the Company Makes Money

aap Implantate generates revenue primarily through the sale of its orthopedic and trauma-related products to hospitals and surgical centers. The company's revenue model is based on direct sales of its implantable devices, which are often sold in conjunction with surgical instruments and services. Key revenue streams include the sale of bone screws, plates, and other implant systems, as well as after-sales services and support. Additionally, aap Implantate may engage in partnerships with healthcare providers and distributors to expand its market reach and enhance its distribution capabilities, contributing to its overall earnings.

aap Implantate Financial Statement Overview

Summary

Revenue growth is positive (8.77%), but profitability remains weak with negative net, EBIT, and EBITDA margins. Leverage has improved (debt-to-equity 0.16), yet returns are still negative, and cash flow remains a major issue with negative operating and free cash flow despite strong FCF growth off a low base.

Income Statement

The company shows a positive revenue growth rate of 8.77% in the latest year, indicating some recovery. However, the net profit margin remains negative, reflecting ongoing profitability challenges. The EBIT and EBITDA margins are also negative, suggesting operational inefficiencies.

Balance Sheet

The debt-to-equity ratio has improved to 0.16, indicating a reduction in leverage. However, the return on equity remains negative, highlighting profitability issues. The equity ratio is stable, suggesting a reasonable level of financial stability.

Cash Flow

Free cash flow has improved significantly, with a growth rate of 454.96%. However, both operating and free cash flows are negative, indicating liquidity challenges. The ratios of cash flow to net income are not favorable, reflecting cash flow inefficiencies.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	12.16M	12.20M	11.48M	11.52M	12.17M	9.33M
Gross Profit	10.56M	10.67M	9.74M	10.58M	2.32M	-2.16M
EBITDA	-1.10M	-1.19M	-3.43M	-1.57M	-520.00K	-5.40M
Net Income	-3.72M	-3.63M	-5.13M	-2.56M	-2.52M	-8.94M
Balance Sheet
Total Assets	13.98M	15.84M	19.47M	20.23M	22.95M	19.71M
Cash, Cash Equivalents and Short-Term Investments	1.07M	2.46M	1.64M	236.00K	2.11M	885.00K
Total Debt	557.00K	1.72M	5.29M	3.17M	5.08M	4.36M
Total Liabilities	4.60M	5.38M	8.63M	7.40M	10.18M	9.41M
Stockholders Equity	9.38M	10.46M	10.85M	12.83M	12.78M	10.29M
Cash Flow
Free Cash Flow	-711.00K	-1.45M	-3.40M	-2.38M	-2.99M	-4.09M
Operating Cash Flow	-292.00K	-1.12M	-2.99M	-1.89M	-2.47M	-3.67M
Investing Cash Flow	-583.00K	-327.00K	-397.00K	-469.00K	155.00K	-140.00K
Financing Cash Flow	652.00K	2.22M	4.42M	475.00K	3.53M	1.77M

aap Implantate Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.26
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:AAQ1, the sentiment is Negative. The current price of 1.26 is below the 20-day moving average (MA) of 1.53, below the 50-day MA of 1.43, and below the 200-day MA of 1.53, indicating a neutral trend. The MACD of 0.01 indicates Positive momentum. The RSI at 45.87 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:AAQ1.

aap Implantate Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
M3V	72 Outperform	€44.41M	14.03	24.14%	3.86%	-5.72%	-25.19%
SBS	63 Neutral	€257.10M	16.05	―	2.71%	-1.64%	22.60%
GME	60 Neutral	€15.84M	8.93	8.35%	3.46%	-23.48%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AAQ1	51 Neutral	€22.37M	-4.37	-34.28%	―	-0.59%	24.03%